In a year marked by new geopolitical and macroeconomic challenges, ProBioGen was able to carry on its rapid growth trajectory by completing a significantly...
"We are running a comprehensive development program for tarcocimab tedromer with topline data from four Phase 3 studies planned for 2023: two for the long-...
Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing ...
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, ...
Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using...
“2022 was a momentous year for HilleVax where the company achieved many important milestones including the initiation and execution of our Phase 2b c...
Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2...
A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related...
© 2024 Biopharma Boardroom. All Rights Reserved.
